Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus FLURAZEPAM HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTRAX versus FLURAZEPAM HYDROCHLORIDE.
CENTRAX vs FLURAZEPAM HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA by increasing the frequency of chloride channel opening.
10-30 mg orally, 3-4 times daily.
15-30 mg orally at bedtime as a single dose for insomnia; maximum dose 30 mg/day.
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Terminal elimination half-life: 40-114 hours (mean 74 hours); accumulates extensively with repeated dosing, leading to prolonged sedation.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Renal: 90% (as metabolites, <1% unchanged); Fecal: <10%; Biliary excretion minimal.
Category C
Category D/X
Benzodiazepine
Benzodiazepine